[Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant]
Posted by rob on January 28, 2010 under Uncategorized | 
Comments are off for this article
| Related Articles |
[Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant]
Nefrologia. 2009;29(6):604-7
Authors: Castillo-Rama M, Grande C, Martínez-Sanchez P, Olavarria E, Marín D, Paz-Artal E, Andrés A, Morales JM
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by clonal expansion of cells in the myeloid line, expressing the BCR-ABL fusion protein responsible for the oncogenic effect of CML. The current frontline therapy in CML is the BCR-ABL tyrosine kinase inhibitor, Imatinib. Although this drug has been shown to improve survival in CML patients, its role in the context of a transplant setting has not been widely described in the literature. We report on the long term molecular remission of CML in a 55 year old man with a second renal transplant who is hepatitis C virus positive, and has associated cardiovascular and immunological risk factors.
PMID: 19936007 [PubMed - indexed for MEDLINE]